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Abstract
Background: Saphenous vein grafts develop an aggressive atherosclerotic process and the efficacy of drug eluting stents
(DES) in treating saphenous vein graft (SVG) lesions has not been convincingly demonstrated. The aim of this study was to
review and analyze the current literature for controlled studies comparing DES versus bare metal stents (BMS) for treatment
of SVG stenoses.
Methodology/Principal Findings: We searched several scientific databases and conference proceedings up to March 15,
2010 for controlled studies comparing target vessel revascularization (TVR) between DES and BMS. Summary odds ratios
(OR) for the primary endpoint TVR and secondary endpoints infarction, stent thrombosis and death were calculated using
random-effect models. A total of 29 studies (3 randomized controlled trials RCT) involving 7549 (202 in RCT) patients were
included. The need for target vessel revascularization in the DES group tended to be lower compared to BMS for the 3 RCT
(OR 0.50 [0.24–1.00]; p=0.051) and for observational studies (0.62 [0.49–0.79]; p,0.001). There was no significant difference
in the risk for myocardial infarction in the RCT (OR 1.25 [0.22–6.99]; p=0.250) but a lower risk for DES based on the
observational studies 0.68 [0.49–0.95]; p=0.023. The risk for stent thrombosis was found to be non-different in the RCT (OR
0.78 [0.03–21.73], p=0.885) while it was in favor of DES in the observational studies (0.58 [0.38 – 0.84]; p,0.001). The
mortality was not significantly different between DES and BMS in the RCT’s (OR 2.22 [0.17 – 29.50]; p=0.546) while the
observation studies showed a decreased mortality in the DES group (0.69 [0.55–0.85]; p,0.001).
Conclusion: DES may decrease TVR rate in treatment of SVG stenoses. No differences in reinfarction rate, stent thrombosis or
mortality was found between the DES and BMS groups in the RCT’s while the observational data showed lower risk for
myocardial infarction, stent thrombosis and death in the DES group. This may be a result of patient selection bias in the
observational studies or represent a true finding that was not the detected in the RCT analysis due to limited statistical power.
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Introduction
Coronary artery bypass graft (CABG) is among the most
frequently performed surgical procedures in the U.S. and Europe
and a mainstay of therapy for coronary artery disease (CAD).
Saphenous vein grafts are the most common type of the grafts used
in coronary by-pass surgery. SVG interventions currently account
for about 5–10% of total percutaneous coronary interventions
(PCI) annually in the United States.[1,2] This number is likely to
increase in the near future since there is emerging evidence that
even lower degree stenoses (30–60%) may profit from stent
implantations;[3] very much in contrast to stenoses in native
vessels where increasing data suggest that only hemodynamically
significant higher degree stenoses should be treated.[4] The
natural and post-interventional biological behaviour of saphenous
vein grafts clearly differs from native vessels, they are at higher risk
for restenosis.[5] While BMS are currently the gold standard for
SVG stenosis, the off-label use of DES has shown promising results
in several observational studies while there is a dearth of
adequately powered randomized trials. [6,7,8] These trials have
produced conflicting results and were rather small.
While DES have demonstrated superiority regarding TVR in
treatment of native coronary arteries, saphenous vein graft stenting
is an entity that has to be investigated specifically. SVG are
different in many regards from arterial vessels. Media layers of the
SVG are thinner than that of coronary arteries, and thus, are more
susceptible to mechanical damage by stents and balloon pressure.
Media fracture has been associated with exaggerated neointimal
PLoS ONE | www.plosone.org 1 June 2010 | Volume 5 | Issue 6 | e11040response.[9] Usually, degenerated vein grafts stenoses consist of
soft friable plaques without fibrous cap. Classical atherogenesis in
contrast probably plays a minor role here. Instead, hypothesized
mechanisms are intimal thrombus formation that converts into
fibrous plaque, change in wall stress (‘‘arterialization’’ of the vein)
and impairment of intrinsic vascular supply.[10,11] This intimal
hyperplasia in the first months after surgery represents the
substrate on which coronary atherosclerosis develops.
The aim of this meta-analysis was to systematically review the
current literature for controlled randomized and non-randomized
studies comparing drug-eluting stents (DES) versus bare-metal
stents (BMS) for treatment of SVG stenoses with a primary focus
on need for re-intervention. Further endpoints of interest were
mortality, stent thrombosis and myocardial infarction.
Methods
Eligibility criteria
Planning and study design was done by two authors (HSG, PM)
including creation of an electronic database with variables of
interest (Microsoft Excel). Primary and secondary endpoints,
variables of interest and search strategy (databases, sources for
unpublished data) were defined in a strategy outline (File S1).
We included controlled (randomized and non-randomized)
studies that compared DES and BMS (with and without the use of
protection devices) in patients with saphenous vein graft (SVG)
stenosis. The outcome of primary interest was TVR and the
secondary outcomes were myocardial infarction, stent thrombosis
or death. Because we expected paucity of data, observational
studies were not excluded a-priori even though the primary focus
was on RCT.
We searched EMBASE, MEDLINE, the Cochrane Central
Register of Controlled Trials, International Pharmaceutical
Abstracts database, ISI Web of Science, and google scholar from
2002 through March 15, 2010. In addition, abstract lists and
conference proceedings from the 2006 to 2010 scientific meetings
of the American College of Cardiology, and the 2006 to 2009
meetings of the European Society of Cardiology, the Transcath-
eter Cardiovascular Therapeutics, and the American Heart
Association were included. We also considered published review
articles, editorials, and internet-based sources of information
(www.tctmd.com, www.theheart.org) to assess potential informa-
tion on studies of interest.
Search strategy for MEDLINE was: ‘‘saphenous vein graft’’ [All
Fields] AND (‘‘bare-metal stent’’ [All Fields] OR ‘‘drug-eluting
stent’’ [All Fields] OR ‘‘paclitaxel-eluting stent’’[All Fields] OR
‘‘sirolimus-eluting stent’’ ’’[All Fields] OR ‘‘everolimus-eluting
stent’’ [All Fields] OR zatarolimus-eluting stent’’ [All Fields] OR
‘‘stents’’ [MeSH Terms]). No restriction on subheadings was
applied. Similar but adapted search terms were used for the other
literature databases.
Reference lists of selected articles were reviewed for other
potentially relevant citations. Authors of selected studies were
contacted to obtain further information. All trials comparing DES
versus BMS in patients with SVG were included in this analysis.
Study selection
In a two-step selection process, two investigators (HSG and PM)
independently reviewed the titles and abstracts of all citations to
identify all potentially relevant studies. In a second step the
corresponding publications were reviewed in full text by the same
two investigators to assess if studies were meeting the following
inclusion criteria: direct comparison of DES vs. BMS, controlled
trial including a BMS control group, and reporting clinical
outcomes (TVR, death, ST or MI; Figure 1). Reviewers were not
Figure 1. Flow chart depicting outline of the search and selection strategy. DES=drug-eluting stent; BMS=bare metal stent;
SVG=saphenous vein graft.
doi:10.1371/journal.pone.0011040.g001
DES vs. BMS in SVG
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was based on agreement of both reviewers.
Data extraction
The relevant information from the articles including baseline
clinical characteristics of the study population was extracted by two
investigators (PM and HSG) into an electronic database. Extracted
data were compared and in case of disagreement original data were
re-checked by both investigators. Where data on the primary
endpoint could not be extracted from the publication, correspond-
ing authors were contacted. We extracted data on the primary
endpoint target vessel revascularization (or target lesion revascular-
ization alternatively), infarction, stent thrombosis and mortality. We
also extracted data on important co-variables (follow up time, mean
age of patients, type of drug-eluting stents used, use of distal embolic
protection device, age of graft).
Data synthesis and analysis
All analyses were performed on an intention-to-treat basis.
Continuity correction was used when an event did not occur in
one group.[12]We evaluated the presence of heterogeneity across
trials with the I
2 statistics. Observational studies and RCT were
combined separately and pooled odds ratios (OR) of effect sizes for
DES compared with BMS were estimated using random-effect
models with the DerSimonian-Laird approach. Publication bias
was evaluated based on the RCT with the Egger’s test and visually
with a funnel plot.[13] For randomized trials, only data from peer-
reviewed publications were used to be able to assess study quality,
proper randomization etc. Published and unpublished data have
been used for observational data, these data are used as a
secondary confirmatory analysis. The quality of each RCT and
the risk for bias in the individual RCT was assessed by two
investigators (HSG, PM) based on the Jadad scale [14]. The score
was used to ensure sufficient quality but was not implemented in
the analyses because of significant limitations of such approach-
es.[14,15] Observational studies are at risk for selection bias and
therefore, we did not mix randomized and non-randomized data
but present the non-randomized data as a secondary confirmatory
analysis. A sensitivity analysis with updated unpublished data from
the randomized trials that has been presented at scientific meetings
has been performed. To evaluate for explanations for heteroge-
neity of study results, the influence of the following factors was
evaluated by stratified analyses: type of DES used in the DES
group, publication date, study size, duration of follow up.
Weighted meta-analytical prevalence estimates for outcome in
DES and BMS patients were calculated using the variance
stabilising Freeman-Tukey double arcsine transformation with an
inverse variance random effects model.[16]All analyses were
performed with R version 2.9.0[17] (packages ‘‘meta’’, ‘‘metafor’’
and ‘‘rmeta’’) and SAS, version 9.2 (SAS Institute, Cary, NC)
(proc mixed).[18] Data for odds ratio and prevalence estimates will
be presented as point estimates followed by 95% confidence
interval estimates in square brackets.
Results
A total of 202 articles were reviewed, and 29 studies including
7549 patients, satisfied the predetermined strict inclusion criteria;
of those, 3692 were treated with a BMS and 3857 with a DES. A
subset of 202 patients were randomly assigned to BMS or DES in
an RCT (Figure 1). [6,7,8,19] One randomized trial is a subgroup
analysis of a larger trial.[7] Tables 1, 2 and 3 summarize the
characteristics of the studies. The other 26 studies (n=7347) were
observational registries.[20,21,22,23,24,25,26,27,28,29,30,31,32,
33,34,35,36,37,38,39,40,41,42,43]. All trials included in this
analysis had sufficient quality and all 3 trials were included in
the analysis (Table S1).
Primary endpoint
TVR. In the 3 RCT, TVR occurred in 22.3% [12.1 – 34.7%]
of patients with DES and in 36.3% [26.9–46.4%] of patients with
BMS. The summary OR was 0.50 [0.24–1.00]; p=0.051;
heterogeneity I
2=16.2%; p=0.303; Figure 2) in favor of DES.
The OR for the observational studies was 0.62 [0.49–0.79];
p,0.001; heterogeneity: I
2=56.3%, p,0.001).
Secondary endpoints
Myocardial infarction. In the 3 RCT, infarction occurred
in 13.7% [7.0–21.7%] of patients after DES implantation
compared to 11.1% [0.5–33.1%] after BMS implantation. The
OR for RCT exclusively was 1.25 [0.22–6.99]; p=0.250;
heterogeneity: I
2=64.8%; p=0.058) (Figure 3). In the
observation studies, the OR for myocardial infarction after DES
compared to DES was found to be 0.68 [0.49–0.95]; p=0.023;
heterogeneity: I
2=23%; p=0.183).
Stent thrombosis. In the 2 RCT reporting on this endpoint,
the OR for DES compared to BMS was 0.78 [.03–21.73],
p=0.885; heterogeneity: I
2=68.2%; p=0.076 (Figure 4). The
Table 1. Characteristics of included randomized trials.
Study N Stent Follow up (mts) Remarks Patient age (yrs) Graft age (yrs) Protection device (%)
BASKET 13 BMS 18 71 na na
34 DES 18 SES and PES 71 na na
Delayed RRISC 37 BMS median 32 72 12.6 na
38 DES median 30.5 SES 73 12.4 na
SOS 39 BMS median 18 67 12.0 56
41 DES median 18 PES 66 11.0 51
BMS: bare-metal stent;
DES: drug-eluting stent;
na: not available;
PES: paclitaxel-eluting stent;
SES: sirolimus-eluting stent;
TLR: target lesion revascularization;
TVR: target vessel revascularization.
doi:10.1371/journal.pone.0011040.t001
DES vs. BMS in SVG
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0.84]; p,0.001; heterogeneity: I
2=0%; p=0.485).
Mortality. For the 3 RCT, the OR for mortality between
DES and BMS was 2.22 (0.17 – 29.50; p=0.546; heterogeneity:
I
2=75.8%; p=0.019). For the observational studies, the OR for
mortality for DES compared to BMS was 0.69 [0.55–0.85];
p,0.001; heterogeneity: I
2=19%; p=0.202] (Figure 5).
Sensitivity and bias analyses
At the scientific meeting of the American College of Cardiology
ACC 2010, longer term follow up data on the SOS trial have been
presented (median 29 months). [44] The inclusion of these longer
term data resulted in similar findings:
For the three RCT and in line with the above described results,
the TVR was lower in the DES groups (OR 0.40 [0.16–0.96],
p=0.0405, heterogeneity: I
2=48%, p=0.147). The myocardial
infarction risk was again not significantly different between the two
groups (OR 1.02 [0.11–9.65], p=0.986; heterogeneity: I
2=79%,
p=0.008). There was no difference in the ST risk (OR 0.71 [0.02–
24.25], p=0.849). The mortality rate was not significantly
different between the groups when considering the longer term
data of the SOS trial (OR 1.92 [0.17–21.33], p=0.597,
heterogeneity: I
2=75%, p=0.019).
Also, we assessed for publication bias of RCT data by the Egger
test and by visual assessment of a funnel plot. For the endpoint
TVR, the Egger test revealed a p value of 0.228.
Heterogeneity assessment
In order to explain the heterogeneity of results for the primary
endpoint among the included studies (RCT and observational
Table 2. Characteristics of included observational studies.
Study N Stent Follow up (mts) Remarks Patient age (yrs) Graft age (yrs) Protection device (%)
Ge et al. 89 BMS 6 na 67 9.2 22.5
61 DES na 67 9.7 31.1
Lee et al. 84 BMS mean 9 69 na 15
139 DES mean 10 211 SES; 78 PES 69 na 19
Chu et al. 57 BMS 12 71 9.4 100
48 DES 12 SES 69 10.1 100
Hoffman et al. 60 BMS 6 (TLR) 67 na 52
60 DES 6 (TLR) PES 67 na 64
Wohrle et al. 26 BMS 12 70 9.1 0
13 DES 12 PES 71 11.4 0
Ellis et al. 175 BMS 12 69 9.8 25.1
175 DES 12 SES 70 10.0 35.6
Minutello et al. 50 BMS mean 20 69 na 48
59 DES mean 21 SES 71 na 71.2
Bansal et al. 72 BMS mean 33 65 na 27
37 DES mean 34 95% SES; 5% PES 68 na 39
Gioia et al. 119 BMS up to 23 70 11.0 na
106 DES up to 23 106 SES; 48 PES 71 11.0 na
Assali et al. 43 BMS 24 71 11.4 48
68 DES 24 SES 70 10.8 38
van Twisk et al. 128 BMS 48 69 na na
122 DES 48 SES, PES 68 na
Vignali et al. 288 BMS median 13.7 71 10.7 na
72 DES median 13.8 na 75 9.0 na
Wilson et al. 281 BMS 9 na na na
418 DES 9 243 SES, 171 PES na na na
May et al. 176 BMS 12 (TLR) 69 na na
201 DES 13 (TLR) na 69 na na
Voudris et al. 40 BMS mean 22.5 na na na
43 DES mean 22.6 90% SES; 10% PES na na na
BMS: bare-metal stent;
DES: drug-eluting stent;
na: not available;
PES: paclitaxel-eluting stent;
SES: sirolimus-eluting stent;
TLR: target lesion revascularization;
TVR: target vessel revascularization.
doi:10.1371/journal.pone.0011040.t002
DES vs. BMS in SVG
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(sirolimus eluting stents (SES) versus paclitaxel eluting stents (PES).
The effect in PES appeared more pronounced in the included
studies compared to SES stents (OR 0.29 [0.14–0.63] versus 0.56
[0.38–0.81]), however, this stent type effect was not found to be
statistically significant (p=0.142)(Figure S1). A second factor that
appears to matter is the time effect. The 2 studies published in
2005 showed an overall odds ratio of 0.19 [0.10–034]in favor of
DES, more recent studies from 2009 and 2010 showed lower
overall benefit for DES (OR 0.78 [0.49–1.23] and OR 0.96
[0.41–2.22], respectively) (Figure S2).
As a third factor, study size appeared to influence the effect size.
According to Egger’s test, there is a significant ‘‘small study effect’’,
smaller studies reported more pronounced superiority of DES
compared to larger studies (bias estimate Egger’s test: 21.71,
standard error 0.77, slope 0.24, p=0.034, Figure S3).
The fourth tested covariate was duration of follow up, which
was not found to relevantly influence outcome (data not shown).
Discussion
In this meta-analysis of 29 studies (3 RCT and 26 observational
studies) including 7549 patients, DES were superior to BMS with
regard to TVR while no difference was found in risk for myocardial
infarction or stent thrombosis in the RCT. The observational studies
revealed a reduced risk for stent thrombosis and mortality risk for
DES and a trend toward decreased infarction. However, these latter
differences may at least partially be explained by selection bias.
Preventing target vessel revascularization with DES may be of
particular importance in SVG, in which stent failure often presents
as an acute coronary syndrome, or with complete SVG lumen
occlusion.[45]
Although restenosis rates are markedly higher in SVG
compared with native vessels, classically, BMS is the treatment
of choice for SVG stenoses[8] while this setting is regarded an off-
label use for DES in the U.S. However, DES are commonly used
in various clinical settings to treat native coronary artery lesions
and have been shown to reduce restenosis rates, especially in
patients with higher risk for restenosis (diabetes mellitus, small
vessels etc.). Saphenous vein graft stenting clearly represents a
higher risk setting. Thus, DES are nowadays increasingly being
used off-label to treat SVG stenoses, there are limited safety and
efficacy data available in this setting. On the other hand, there
have been even increased concerns and data suggesting that the
effect of DES may be attenuated by the different biological
properties of vein grafts or that DES may even be harmful.[9,19]
Due to a lack of clear evidence of optimal stent choice in
saphenous vein grafts with only few small randomized trials, the
Table 3. Characteristics of included observational studies (continued).
Study N Stent Follow up (mts) Remarks Patient age (yrs) Graft age (yrs) Protection device (%)
Moore et al. 173 BMS 12 (TLR) 67 na na
171 DES 13 (TLR) SES,PES 69 na na
Okabe et al. 344 BMS 12 70 na 21
138 DES 12 17 SES; 66 PES 70 na 26
Applegate et al. 74 BMS 24 69 na 47
74 DES 24 67 SES; 7 PES 69 na 53
Shishehbor et al. 349 BMS 35 69 na 30
217 DES 35 na 70 na 56
Lozano et al. 114 BMS 30 71 121 na
98 DES 30 na 66 108 na
Brodie et al. 343 BMS 9 69 na 33.7
785 DES 9 59% SES, 38% PES, 3%
both
68 na 37.3
Ramana et al. 170 BMS mean 34 69.1 12.9 na
141 DES mean 34 100% SES 70 11.5 na
Kaplan et al. 33 BMS 12 70.5 7.6 na
37 DES 12 100% SES 72.3 7.5 na
Jin-cheng et al. 47 BMS 12 71 na 31
50 DES 12 mixed 74 na 30
Goswami et al. 95 BMS 36 (TLR) 69.5 na na
284 DES 36 (TLR) 84% SES, 16% PES 70.7 na na
Latib et al. 174 BMS 24 na na na
127 DES 24 na na na na
BMS: bare-metal stent;
DES: drug-eluting stent;
na: not available;
PES: paclitaxel-eluting stent;
SES: sirolimus-eluting stent;
TLR: target lesion revascularization;
TVR: target vessel revascularization.
doi:10.1371/journal.pone.0011040.t003
DES vs. BMS in SVG
PLoS ONE | www.plosone.org 5 June 2010 | Volume 5 | Issue 6 | e11040Figure 2. The Forest plot of odds ratios (OR) of target-vessel revascularization (TVR). Sizes of data markers are propo rtional to the weight
of each study in the meta-analysis. Horizontal bars, 95% confidence intervals (CI). Observational=observational, non-randomized controlled studies;
DES=drug-eluting stent; BMS=bare metal stent; RCT=randomized controlled trials.
doi:10.1371/journal.pone.0011040.g002
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and this debate is still ongoing. The use of drug-eluting stents has
decreased dramatically in many centers after data about increased
risk for stent thrombosis and other negative aspects of coated stents
have been published.[46,47,48]
Heterogeneity among studies
Randomized controlled trials: The most significant reduction in
the primary endpoint TVR was found in the BASKET trial, [7]
the least effect in the Delayed RRISC trial [19] while the effect in
the SOS trial [8] was somewhat in between. One difference of
potential importance is the type of drug eluting stent that was used.
While RRISC used sirolimus eluting stents (SES), SOS used
paclitaxel eluting stents (PES), in the BASKET trial, both stent
types were used. There may be a difference in the effectiveness of
these substances when used in vein grafts. Another probably
important difference among the studies is the difference in follow
up interval. In the Delayed RRISC study, median follow up
duration was 30.5–32 months, for BASKET and SOS it was 18
months. An interim analysis with shorter term results of the
Figure 3. The Forest plot of odds ratios (OR) of myocardial infarction. Sizes of data markers are proportional to the weight of each study in
the meta-analysis. Horizontal bars, 95% CI. Observational=observational, non-randomized controlled studies; DES=drug-eluting stent; BMS=bare
metal stent; RCT=randomized controlled trials.
doi:10.1371/journal.pone.0011040.g003
DES vs. BMS in SVG
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risk reduction of 0.19 (95% CI 0.05 to 0.83) for BMS, [6] while at
30.5–32 months, the relative risk reduction was only 0.90 [0.49–
1.65]. [19] There seems to be a more pronounced early benefit
while longer-term benefits seem less pronounced as described
above. Recent observational data also suggested a late ‘‘catch-up’’
phenomenon regarding TVR with a clear benefit for DES in the
first year but similar longer term results.[49] It seems plausible
that, after the coating drug has completely eluted, the beneficial
effect of DES compared to BMS decreases. Due to the different
biological properties of saphenous vein grafts, this late ‘‘catch up’’
phenomenon may be more pronounced than in native vessels.
Moreover, the RRISC delayed trial found that patients with SES
had higher mortality rates than their BMS counterparts and
similar rates of TVR on the long term. [6,19].
Overall (observational studies and RCT): While the study
heterogeneity in the RCT was limited, the results between the
studies differed significantly when also considering observational
studies. Several factors may significantly contribute to this
heterogeneity:
First, type of drug eluting stent: The effect in PES appeared
more pronounced in the included studies compared to SES stents
(OR 0.294 [0.138–0.628] versus 0.555 [0.380–0.811]). This is in
line with the finding in the RCT as described above, where the
SOS trial using PES showed a more pronounced effect. Thus, the
coating drug may play a significant role. While SES have proven
to be more effective in native coronary vessels,[50] PES may be
more effective in vein grafts (Figure S1). Second, time effect: While
early studies (published in 2005) show a very impressive effect of
DES, later studies found less benefit for DES compared to BMS.
This may be related to changes of the tested stents themselves, it
may also be related to other time-dependent co-factors. An
improvement of the comparator (BMS) over time could have
resulted in smaller differences compared to DES. Of note, the
medical co-treatments have changes as well over time (improve-
ment in lipid-lowering treatment, anti-platelet therapy etc.),
leading to a general reduction in need for revascularizations and
therefore, less significant differences between the two stents in this
regard (Figure S2). We have observed a similar time effect in
another setting of stenting, i.e., in carotid artery stenosis, where
Figure 4. The Forest plot of odds ratios (OR) of stent thrombosis (ST). Sizes of data markers are proportional to the weight of each study in
the meta-analysis. Horizontal bars, 95% CI. Observational=observational, non-randomized controlled studies; DES=drug-eluting stent; BMS=bare
metal stent; RCT=randomized controlled trials.
doi:10.1371/journal.pone.0011040.g004
DES vs. BMS in SVG
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endarterectomy) relevantly decreased over time.[51] Third, study
size: According to Egger’s test, there seems to be a significant
‘‘small study effect’’, small studies showed more pronounced effects
than larger studies which may be due to publication bias (Egger’s
test p value=0.034). This is illustrated in the linear regression plot
of normalized effect sizes against precision (reciprocal of the
standard error of the estimate) (Figure S3). Fourth, there is a wide
range of follow up duration among the included studies. While this
may have influenced the findings in the RCT, it does not appear
Figure 5. The Forest plot of odds ratios (OR) of mortality. Sizes of data markers are proportional to the weight of each study in the meta-
analysis. Horizontal bars, 95% CI. Observational=observational, non-randomized controlled studies; DES=drug-eluting stent; BMS=bare metal stent;
RCT=randomized controlled trials.
doi:10.1371/journal.pone.0011040.g005
DES vs. BMS in SVG
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adds to the overall heterogeneity as well.
Limitations
The main limitation of this study is the small number of RCT
available for inclusion. Furthermore, each of the 3 RCT was
rather small. [6,7,8] Therefore, the statistical power of this analysis
is small and the primary endpoint, TVR, did not quite reach
statistical significance. Thus, it is too early to draw strong
conclusions based on these limited available data. However, the
meta-analysis of the observational studies are reflecting the ‘‘real-
world ’’ and further support the conclusion but observational data
are of course prone to bias toward patient selection. [23] It also has
to be noted that evaluation of publication bias cannot be done in a
robust manner with such few data points, the statistical power of
the Egger’s test to suspect publication bias is very limited here.
We have to acknowledge that even our pooled analysis is very
limited in statistical power and the results showed only a
borderline significance for TVR. On the other hand, the
observational studies in this meta-analysis support that DES may
be beneficial regarding TVR in SVG. Observational data are, of
course, prone to bias due to non-random treatment allocation.
Further, it must be noted that a majority of the studies had a short
follow-up period (6–12 months).
Conclusion
The use of DES may be superior to the use BMS for treatment
of SVG with regard to TVR but this finding is mainly based on
observational data while the analysis based on 3 small RCT did
not reach statistical significance. However, the finding is supported
by a significant reduction in TVR seen in observational studies.
Based on the RCT data, there are probably no major differences
in safety endpoints such as myocardial infarction, stent thrombosis
or mortality while observational data indicate lower risk for death,
stent thrombosis and myocardial infarction for the DES group, a
finding that may reflect selection bias in these observational studies
or a true finding that was not detected in the RCT due to lack of
statistical power.
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Table S1 Study quality of included randomized controlled trials
according to the Jadad score.
Found at: doi:10.1371/journal.pone.0011040.s004 (0.04 MB
DOC)
File S1 Study plan and abstract form.
Found at: doi:10.1371/journal.pone.0011040.s005 (0.03 MB
DOC)
Acknowledgments
We are especially grateful to Dr. R. J. Applegate, Wake Forest University
School of Medicine for sharing unpublished data, to Whitney Townsend,
Librarian, Taubman Medical Library, University of Michigan, for her
valuable inputs during the literature search and to Michelle Smith, RN, for
her help with data management.
Author Contributions
Conceived and designed the experiments: PM HSG. Performed the
experiments: PM. Analyzed the data: PM GK. Wrote the paper: PM. Re-
confirmed data accuracy: ESB. Interpreted the data: ESB RC GK MHS.
Revised the paper critically for important intellectual content: ESB RC GK
MHS. Performed independent statistical analyses of the data: GK.
References
1. Wilson CT, Fisher ES, Welch HG, Siewers AE, Lucas FL (2007) U.S. trends in
CABG hospital volume: the effect of adding cardiac surgery programs. Health
Aff (Millwood) 26: 162–168.
2. Brilakis ES, Wang TY, Rao SV, Banerjee S, Dai D, et al. (2010) Frequency and
Predictors of Drug-Eluting Stent Use in Saphenous Vein Bypass Graft
Percutaneous Coronary Interventions: A Report from the American College
of Cardiology - National Cardiovascular Data Registry (abstract). presented at
American College of Cardiology ACC scientific meetings 2010, March 14;
Atlanta, Georgia.
3. Rodes-Cabau J, Bertrand OF, Larose E, Dery JP, Rinfret S, et al. (2009)
Comparison of plaque sealing with paclitaxel-eluting stents versus medical
therapy for the treatment of moderate nonsignificant saphenous vein graft
lesions: the moderate vein graft lesion stenting with the taxus stent and
intravascular ultrasound (VELETI) pilot trial. Circulation 120: 1978–1986.
4. Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, et al. (2009) Fractional
flow reserve versus angiography for guiding percutaneous coronary intervention.
N Engl J Med 360: 213–224.
5. Safian RD (2002) Accelerated atherosclerosis in saphenous vein bypass grafts: a
spectrum of diffuse plaque instability. Prog Cardiovasc Dis 44: 437–448.
6. Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, et al.
(2006) Randomized double-blind comparison of sirolimus-eluting stent versus
bare-metal stent implantation in diseased saphenous vein grafts: six-month
angiographic, intravascular ultrasound, and clinical follow-up of the RRISC
Trial. J Am Coll Cardiol 48: 2423–2431.
7. Jeger RV, Schneiter S, Kaiser C, Bonetti PO, Brunner-La Rocca H, et al. (2009)
Drug-eluting stents compared with bare metal stents improve late outcome after
saphenous vein graft but not after large native vessel interventions. Cardiology
112: 49–55.
8. Brilakis ES, Lichtenwalter C, de Lemos JA, Roesle M, Obel O, et al. (2009) A
randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-
metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein
Grafts) trial. J Am Coll Cardiol 53: 919–928.
9. Ribichini F, Pugno F, Ferrero V, Wijns W, Vacca G, et al. (2008) Long-term
histological and immunohistochemical findings in human venous aorto-coronary
bypass grafts. Clin Sci (Lond) 114: 211–220.
10. Brody WR, Kosek JC, Angell WW (1972) Changes in vein grafts following aorto-
coronary bypass induced by pressure and ischemia. J Thorac Cardiovasc Surg
64: 847–854.
11. Bulkley BH, Hutchins GM (1977) Accelerated ‘‘atherosclerosis’’. A morphologic
study of 97 saphenous vein coronary artery bypass grafts. Circulation 55:
163–169.
12. Sankey S, Weissfeld L, Fine M, et al. (1996) An assessment of the use of the
continuity correction for sparse data in metanalysis. Communications in
Statistics: Simulation and Computation 25: 1031–1056.
13. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis
detected by a simple, graphical test. BMJ 315: 629–634.
14. Brouwers MC, Johnston ME, Charette ML, Hanna SE, Jadad AR, et al. (2005)
Evaluating the role of quality assessment of primary studies in systematic reviews
of cancer practice guidelines. BMC Med Res Methodol 5: 8.
15. Juni P, Witschi A, Bloch R, Egger M (1999) The hazards of scoring the quality of
clinical trials for meta-analysis. JAMA 282: 1054–1060.
16. Miller J (1978) The inverse of the Freeman-Tukey double arcsine transforma-
tion. The American Statistician 32.
17. R Development Core Team (2009) R: A language and environment for
statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
ISBN 3-900051-07-0, R project website (2010) http://www.R-project.org.
DES vs. BMS in SVG
PLoS ONE | www.plosone.org 10 June 2010 | Volume 5 | Issue 6 | e1104018. Hartung J, Knapp G, Sinha BK (2008) Statistical Meta-Analysis with
Applications. Hoboken, NJ: Wiley-Interscience.
19. Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, et al.
(2007) Increased late mortality after sirolimus-eluting stents versus bare-metal
stents in diseased saphenous vein grafts: results from the randomized DELAYED
RRISC Trial. J Am Coll Cardiol 50: 261–267.
20. Shishehbor MH, Hawi R, Singh IM, Tuzcu EM, Bhatt DL, et al. (2009) Drug-
eluting versus bare-metal stents for treating saphenous vein grafts. Am Heart J
158: 637–643.
21. Chu WW, Rha SW, Kuchulakanti PK, Cheneau E, Torguson R, et al. (2006)
Efficacy of sirolimus-eluting stents compared with bare metal stents for
saphenous vein graft intervention. Am J Cardiol 97: 34–37.
22. Ge L, Iakovou I, Sangiorgi GM, Chieffo A, Melzi G (2005) Treatment of
saphenous vein graft lesions with drug-eluting stents: immediate and midterm
outcome. J Am Coll Cardiol 45: 989–994.
23. Lee MS, Shah AP, Aragon J, Jamali A, Dohad S, et al. (2005) Drug-eluting
stenting is superior to bare metal stenting in saphenous vein grafts. Catheter
Cardiovasc Interv 66: 507–511.
24. Hoffmann R, Pohl T, Koster R, Blindt R, Boeckstegers P, et al. (2007)
Implantation of paclitaxel-eluting stents in saphenous vein grafts: clinical and
angiographic follow-up results from a multicentre study. Heart 93: 331–334.
25. Wohrle J, Nusser T, Kestler HA, Kochs M, Hombach V (2007) Comparison of
the slow-release polymer-based paclitaxel-eluting Taxus-Express stent with the
bare-metal Express stent for saphenous vein graft interventions. Clin Res Cardiol
96: 70–76.
26. Ellis SG, Kandzari D, Kereiakes DJ, Pichard A, Huber K, et al. (2007) Utility of
sirolimus-eluting Cypher stents to reduce 12-month target vessel revasculariza-
tion in saphenous vein graft stenoses: results of a multicenter 350-patient case-
control study. J Invasive Cardiol 19: 404–409.
27. Minutello RM, Bhagan S, Sharma A, Slotwiner AJ, Feldman DN, et al. (2007)
Long-term clinical benefit of sirolimus-eluting stents compared to bare metal
stents in the treatment of saphenous vein graft disease. J Interv Cardiol 20:
458–465.
28. Wilson BH, Humphrey AD, Cedarholm JC, Elliot CM, Haber RH, et al. (2007)
Drug-eluting stents are no better than bare metal stents in vein grafts: results
from the strategic transcatheter evaluation of new therapies (STEMT) group
(abstract). American College of Cardiology ACC/i2 scientific meetings, March
25, 2007 Chicago, IL.
29. Voudris V, Kalianos C, Patsilinakos S, Manginas A, Pavlides G, et al. (2006)
Effectiveness of drug-eluting stents in the treatment of bypass graft lesions
(abstract). Eur Heart J 2006, 27(Abstract Suppl): 925.
30. Moore PA, Toney BM, Hermiller JB (2007) Off label use of drug-eluting stents:
no advantage in saphenous vein grafts (abstract). Presented at Transcatheter
Cardiovascular Therapeutics TCT meeting, Washington, DC, 2007.
31. Bansal D, Muppidi R, Singla S, Sukhija R, Zarich S, et al. (2008) Percutaneous
intervention on the saphenous vein bypass grafts–long-term outcomes. Catheter
Cardiovasc Interv 71: 58–61.
32. Gioia G, Benassi A, Mohendra R, Chowdhury K, Masood I, et al. (2008) Lack
of clinical long-term benefit with the use of a drug eluting stent compared to use
of a bare metal stent in saphenous vein grafts. Catheter Cardiovasc Interv 72:
13–20.
33. Assali A, Raz Y, Vaknin-Assa H, Ben-Dor I, Brosh D, et al. (2008) Beneficial 2-
years results of drug-eluting stents in saphenous vein graft lesions. EuroInterven-
tion 4: 108–114.
34. van Twisk PH, Daemen J, Kukreja N, van Domburg RT, Serruys PW (2008)
Four-year safety and efficacy of the unrestricted use of sirolimus- and paclitaxel-
eluting stents in coronary artery bypass grafts. EuroIntervention 4: 311–317.
35. Vignali L, Saia F, Manari A, Santarelli A, Rubboli A, et al. (2008) Long-term
outcomes with drug-eluting stents versus bare metal stents in the treatment of
saphenous vein graft disease (results from the REgistro Regionale AngiopLas-
tiche Emilia-Romagna registry). Am J Cardiol 101: 947–952.
36. May HT, Bair TL, Muhlestein JB, Horne BD, Li Q, et al. (2008) Use of Drug-
Eluting Stents in Saphenous Vein Graft Lesions (abstract) Journal of the
American College of Cardiology, March 11, 2008, Volume 51, Issue 10,
Supplement A.
37. Okabe T, Lindsay J, Buch AN, Steinberg DH, Roy P, et al. (2008) Drug-eluting
stents versus bare metal stents for narrowing in saphenous vein grafts.
Am J Cardiol 102: 530–534.
38. Applegate RJ, Sacrinty M, Kutcher M, Santos R, Gandhi S, et al. (2008) Late
outcomes of drug-eluting versus bare metal stents in saphenous vein grafts:
Propensity score analysis. Catheter Cardiovasc Interv 72: 7–12.
39. Lozano I, Garcia-Camarero T, Carrillo P, Baz JA, de la Torre JM, et al. (2009)
[Comparison of drug-eluting and bare metal stents in saphenous vein grafts.
Immediate and long-term results]. Rev Esp Cardiol 62: 39–47.
40. Ramana RK, Ronan A, Cohoon K, Homan D, Sutherland J, et al. (2008) Long-
term clinical outcomes of real-world experience using sirolimus-eluting stents in
saphenous vein graft disease. Catheter Cardiovasc Interv 71: 886–893.
41. Kaplan S, Barlis P, Kiris A, Dimopoulos K, Celik S, et al. (2008) Immediate
procedural and long-term clinical outcomes following drug-eluting stent
implantation to ostial saphenous vein graft lesions. Acute Card Care 10: 88–92.
42. Jin-cheng G, Min X, Guo-zhong W, Chang-sheng M (2008) Late lumen loss of
drug eluting stents versus bare mental stents for saphenous vein graft
intervention. Journal of Clinical Rehabilitative Tissue Engineering Research
12: 6971–6975.
43. Latib A, Ferri L, Cosgrave J, Godino C, Romagnoli E, et al. (2008) A
comparison of the long-term (2 year) safety and efficacy of drug-eluting and
bare-metal stent implantation in saphenous vein grafts (abstract). Eur Heart J 29
(Supplement): 455–456.
44. Lichtenwalter C, de Lemos JA, Obel O, Abdel-karim AR, Roesle M, et al.
(2010) Persistent Benefit From Paclitaxel-Eluting Stent Implantation in
Saphenous Vein Grafts: Long-Term Results of the Stenting Of Saphenous
Vein Grafts (SOS) Trial (abstract); presented at American College of Cardiology
ACC scientific meetings 2010, March 14; Atlanta, Georgia.
45. Lichtenwalter C, de Lemos JA, Roesle M, Obel O, Holper EM, et al. (2009)
Clinical presentation and angiographic characteristics of saphenous vein graft
failure after stenting: insights from the SOS (stenting of saphenous vein grafts)
trial. JACC Cardiovasc Interv 2: 855–860.
46. Meier P, Gurm HS Drug-eluting versus bare metal stents–a one horse race?
J Invasive Cardiol 22: 33–34.
47. Gualano SK, Gurm HS, Share D, Smith D, Aronow HD, et al. (2010) Temporal
Trends in the Use of Drug-eluting Stents for Approved and Off-label
Indications: A Longitudinal Analysis of a Large Multicenter Percutaneous
Coronary Intervention Registry. Clin Cardiol 33: 111–116.
48. Meier P, Zbinden R, Togni M, Wenaweser P, Windecker S, et al. (2007)
Coronary collateral function long after drug-eluting stent implantation. J Am
Coll Cardiol 49: 15–20.
49. Brodie BR, Wilson H, Stuckey T, Nussbaum M, Laurent S, et al. (2009)
Outcomes with drug-eluting versus bare-metal stents in saphenous vein graft
intervention results from the STENT (strategic transcatheter evaluation of new
therapies) group. JACC Cardiovasc Interv 2: 1105–1112.
50. Gurm HS, Boyden T, Welch KB (2008) Comparative safety and efficacy of a
sirolimus-eluting versus paclitaxel-eluting stent: a meta-analysis. Am Heart J 155:
630–639.
51. Meier P, Knapp G, Tamhane U, Chaturvedi S, Gurm HS (2010) Short term
and intermediate term comparison of endarterectomy versus stenting for carotid
artery stenosis: systematic review and meta-analysis of randomised controlled
clinical trials. BMJ 340: c467.
DES vs. BMS in SVG
PLoS ONE | www.plosone.org 11 June 2010 | Volume 5 | Issue 6 | e11040